Therapeutic Angiogenesis: From Single-Factor Failures to Precision Vascular Regeneration
Integrative Biomedical Research · 01.04.2026 · 10 (1) · 1-26
DOI: 10.25163/biomedical.10110794 ↗Kurz gefasst
Fachartikel in der Zeitschrift Integrative Biomedical Research, online erschienen am 01.04.2026.
Abstract (Originalsprache)
Ischemic vascular diseases, including peripheral artery disease, chronic limb-threatening ischemia, ischemic heart disease, diabetic ulcers, and stroke, remain major causes of morbidity, mortality, disability, and healthcare expenditure worldwide. Despite significant advances in surgical and endovascular revascularization, a substantial proportion of patients remain unsuitable for conventional interventions, creating an urgent need for regenerative strategies capable of restoring tissue perfusion and promoting functional repair. Therapeutic angiogenesis, the controlled induction of new blood vessel formation, has emerged as a promising approach for addressing this unmet clinical need. However, early angiogenic therapies based primarily on single growth-factor delivery produced inconsistent clinical outcomes, highlighting the complexity of vascular regeneration and the limitations of reductionist therapeutic designs. This review critically examines the biological foundations, historical evolution, translational progress, and public health relevance of therapeutic angiogenesis. Particular emphasis is placed on recent advances in gene-based therapies, stem and progenitor cell approaches, engineered extracellular vesicles, biomaterial-assisted delivery systems, hypoxia-responsive platforms, and metabolic and immune regulatory mechanisms that collectively shape angiogenic responses. We further discuss disease-specific applications in chronic limb-threatening ischemia, diabetic wound healing, myocardial repair, bone regeneration, and other ischemic disorders, while highlighting contexts in which angiogenic stimulation may be detrimental, such as retinal neovascular diseases. Emerging evidence indicates that successful vascular regeneration requires coordinated modulation of endothelial signaling, immune responses, extracellular matrix remodeling, metabolic adaptation, and vessel maturation rather than isolated stimulation of endothelial proliferation. Finally, we evaluate key translational challenges, including safety concerns, delivery efficiency, manufacturing scalability, patient stratification, regulatory considerations, and implementation in resource-limited settings. Collectively, current evidence suggests that next-generation, multimodal, and precision-guided angiogenic therapies may overcome historical barriers and enable clinically meaningful vascular regeneration, positioning therapeutic angiogenesis as an increasingly important component of future regenerative medicine and public health strategies.
Zitieren
APA
(2026). Therapeutic Angiogenesis: From Single-Factor Failures to Precision Vascular Regeneration. Integrative Biomedical Research, 10(1), 1-26. https://doi.org/10.25163/biomedical.10110794
Vancouver
Therapeutic Angiogenesis: From Single-Factor Failures to Precision Vascular Regeneration. Integrative Biomedical Research. 2026;10(1):1-26. doi:10.25163/biomedical.10110794
BibTeX
@article{euvimed2026,
title = {Therapeutic Angiogenesis: From Single-Factor Failures to Precision Vascular Regeneration},
journal = {Integrative Biomedical Research},
year = {2026},
volume = {10},
number = {1},
pages = {1--26},
doi = {10.25163/biomedical.10110794}
}
EUVIMED